SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) - rationale, methodology and design

2023-11-18 endocrinology Title + abstract only

Show abstract

IntroductionType 2 diabetes (T2D) is associated with severe complications, including chronic kidney disease (CKD), cardiovascular disease, heart failure and premature death. By the time T2D is diagnosed, many patients already have emerging complications. Therefore, early treatment has the potential for prevention or even early reversal of serious complications. However, until recently, it was not well-defined which patients were most at risk of developing complications in the stage of prediabete...

SGLT2 inhibition in addition to lifestyle intervention and risk for complications in subtypes of patients with prediabetes - a randomized, placebo controlled, multi-center trial (LIFETIME) - rationale, methodology and design

Predicted journal destinations